{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:03:31Z","timestamp":1761743011880},"reference-count":64,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,8,28]],"date-time":"2007-08-28T00:00:00Z","timestamp":1188259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Surgical Oncology"],"published-print":{"date-parts":[[2007,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The majority of Neuroendocrine tumors (NET) express somatostatin (SS) receptors, and thus can be successfully targeted with radiolabeled SS analogs in vivo. Somatostatin receptor scintigraphy (SRS) with <jats:sup>111<\/jats:sup>In\u2010DTPA Octreotide is the main imaging technique for evaluation of NETs. Radio\u2010guided surgery for NETs, therefore, primarily utilizes <jats:sup>111<\/jats:sup>In\u2010DTPA Octreotide tumor localization mechanism and kinetics. Somatostatin analog radiopharmacy continues to evolve to include the development of more selective and higher affinity analogs and PET tracers. These changes are expected to open new venues for radio\u2010guided surgery technology. J. Surg. Oncol. 2007;96:309\u2013315. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jso.20868","type":"journal-article","created":{"date-parts":[[2007,8,28]],"date-time":"2007-08-28T15:46:37Z","timestamp":1188315997000},"page":"309-315","source":"Crossref","is-referenced-by-count":24,"title":["Radio\u2010guided surgery in neuroendocrine tumors"],"prefix":"10.1002","volume":"96","author":[{"given":"Seza A","family":"Gulec","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Baum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,28]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1184-3"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1184-3"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050034"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2002-0007"},{"key":"e_1_2_1_6_2","first-page":"BP140","article-title":"111In\u2010pentetreotide scintigraphy: Procedure guidelines for tumour imaging","volume":"30","author":"Bombardieri E","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"e_1_2_1_7_2","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/000313480106701108","article-title":"Antiangiogenic therapy with somatostatin receptor\u2010mediated in situ radiation","volume":"67","author":"Gulec SA","year":"2001","journal-title":"Am Surg"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1053\/snuc.2002.31020"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2001.6149"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/000313480106701108","article-title":"Antiangiogenic therapy with somatostatin receptor\u2010mediated in situ radiation","volume":"67","author":"Gulec SA","year":"2001","journal-title":"Am Surg"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2006.03.007"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389450033346830"},{"key":"e_1_2_1_13_2","first-page":"359","article-title":"Somatostatin receptor scintigraphy in liver metastasis detection from gastroenteropancreatic neuroendocrine tumors","volume":"44","author":"Schillaci O","year":"2003","journal-title":"J Nucl Med"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1159\/000080742"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200007000-00015"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006231-199306000-00006"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/000313480206800803","article-title":"Cytoreductive surgery in patients with advanced\u2010stage carcinoid tumors","volume":"68","author":"Gulec SA","year":"2002","journal-title":"Am Surg"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.0.0100469"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02050937"},{"key":"e_1_2_1_20_2","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1177\/000313480206800803","article-title":"Cytoreductive surgery in patients with advanced\u2010stage carcinoid tumors","volume":"68","author":"Gulec SA","year":"2002","journal-title":"Am Surg"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000161981.58631.ab"},{"key":"e_1_2_1_22_2","first-page":"1155","article-title":"Intraoperative gamma probe detection of neuroendocrine tumors","volume":"39","author":"Adams S","year":"1998","journal-title":"J Nucl Med"},{"key":"e_1_2_1_23_2","first-page":"745","article-title":"Intraoperative localization of neuroendocrine tumors with 125I\u2010TYR(3)\u2010octreotide and a hand\u2010held gamma\u2010detecting probe","volume":"114","author":"Schirmer WJ","year":"1993","journal-title":"Surgery"},{"key":"e_1_2_1_24_2","first-page":"1139","article-title":"Detection of occult gastrinomas with iodine 125\u2010labeled lanreotide and intraoperative gamma detection","volume":"116","author":"Woltering EA","year":"1994","journal-title":"Surgery"},{"key":"e_1_2_1_25_2","first-page":"1155","article-title":"Intraoperative gamma probe detection of neuroendocrine tumors","volume":"39","author":"Adams S","year":"1998","journal-title":"J Nucl Med"},{"key":"e_1_2_1_26_2","first-page":"853","article-title":"Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors","volume":"38","author":"Lebtahi R","year":"1997","journal-title":"J Nucl Med"},{"key":"e_1_2_1_27_2","first-page":"1155","article-title":"Intraoperative gamma probe detection of neuroendocrine tumors","volume":"39","author":"Adams S","year":"1998","journal-title":"J Nucl Med"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12 <2490::AID-CNCR21>3.0.CO;2-6"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197304)31:4<915::AID-CNCR2820310424>3.0.CO;2-A"},{"key":"e_1_2_1_31_2","first-page":"1155","article-title":"Intraoperative gamma probe detection of neuroendocrine tumors","volume":"39","author":"Adams S","year":"1998","journal-title":"J Nucl Med"},{"key":"e_1_2_1_32_2","first-page":"745","article-title":"Intraoperative localization of neuroendocrine tumors with 125I\u2010TYR(3)\u2010octreotide and a hand\u2010held gamma\u2010detecting probe","volume":"114","author":"Schirmer WJ","year":"1993","journal-title":"Surgery"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2006.05.047"},{"key":"e_1_2_1_34_2","first-page":"1144","article-title":"New octreotide derivatives labelled with technetium\u201099m","volume":"37","author":"Maecke HR","year":"1996","journal-title":"J Nucl Med"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050398"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm980602h"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100639"},{"key":"e_1_2_1_38_2","first-page":"762","article-title":"Comparison of 111In\u2010DOTA\u2010Tyr3\u2010octreotide and 111In\u2010DTPA\u2010octreotide in the same patients: Biodistribution, kinetics, organ and tumor uptake","volume":"40","author":"Kwekkeboom DJ","year":"1999","journal-title":"J Nucl Med"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590050476"},{"key":"e_1_2_1_40_2","first-page":"610","article-title":"Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y\u2010DOTATOC","volume":"43","author":"Waldherr C","year":"2002","journal-title":"J Nucl Med"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100490"},{"key":"e_1_2_1_42_2","first-page":"55S","article-title":"MIBG and somatostatin receptor analogs in children: Current concepts on diagnostic and therapeutic use","volume":"46","author":"Pashankar FD","year":"2005","journal-title":"J Nucl Med"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01116"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00761-004-0716-1"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-004-1697-4"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002590100639"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-004-1697-4"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-003-1255-5"},{"key":"e_1_2_1_49_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm980602h"},{"key":"e_1_2_1_50_2","first-page":"213","article-title":"64Cu\u2010TETA\u2010octreotide as a PET imaging agent for patients with neuroendocrine tumors","volume":"42","author":"Anderson CJ","year":"2001","journal-title":"J Nucl Med"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-002-1012-1"},{"key":"e_1_2_1_52_2","first-page":"S54","article-title":"Receptor PET\/CT imaging of neuroendocrine tumors using the Ga\u201068 labelled, high affinity somatostatin analogue DOTA\u20101\u2010Na13\u2010octreotide (DOTA\u2010NOC): Clinical results in 327 patients","volume":"32","author":"Baum RP","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"e_1_2_1_53_2","first-page":"C\u20100409","article-title":"Receptor\u2010PET\/CT of neuroendocrine tumors using the gallium\u201068 labelled somatostatin analog DOTA\u2010NOC: First clinical results","volume":"15","author":"Baum RP","year":"2005","journal-title":"Eur Radiol"},{"key":"e_1_2_1_54_2","first-page":"1053","article-title":"PET imaging of somatostatin receptors using [68GA]DOTA\u2010D\u2010Phe1\u2010Tyr3\u2010octreotide: First results in patients with meningiomas","volume":"42","author":"Henze M","year":"2001","journal-title":"J Nucl Med"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00173043"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2004.11.016"},{"key":"e_1_2_1_57_2","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.1998.16.7.2534","article-title":"Positron emission tomography with 5\u2010hydroxytryprophan in neuroendocrine tumors","volume":"16","author":"Orlefors H","year":"1998","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0969-8051(99)00085-2"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1938"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869309083911"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1053\/snuc.2002.31028"},{"key":"e_1_2_1_62_2","first-page":"70","article-title":"Metabolic and receptor imaging of metastatic medullary thyroid cancer: Does anti\u2010CEA and somatostatin\u2010receptor scintigraphy allow for prognostic predictions?","volume":"26","author":"Behr TM","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"e_1_2_1_63_2","first-page":"1172","article-title":"Radioimmunodetection of medullary thyroid carcinoma using indium\u2010111 bivalent hapten and anti\u2010CEA\u2009\u00d7\u2009anti\u2010DTPA\u2010indium bispecific antibody","volume":"39","author":"Barbet J","year":"1998","journal-title":"J Nucl Med"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01254467"},{"key":"e_1_2_1_65_2","first-page":"33","article-title":"Pentavalent [99mTc]DMSA, [131I]MIBG, and [99mTc]MDP\u2014an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid","volume":"29","author":"Clarke SE","year":"1988","journal-title":"J Nucl Med"}],"container-title":["Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.20868","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjso.20868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jso.20868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T18:06:22Z","timestamp":1694455582000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jso.20868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,28]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,9,15]]}},"alternative-id":["10.1002\/jso.20868"],"URL":"https:\/\/doi.org\/10.1002\/jso.20868","archive":["Portico"],"relation":{},"ISSN":["0022-4790","1096-9098"],"issn-type":[{"value":"0022-4790","type":"print"},{"value":"1096-9098","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,28]]}}}